Jennifer Williams, MD
Pulmonary Disease · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 1
- 1 carrier
- Offices
- 3
Offices
3 locations · Stanford Health Care · University Healthcare Alliance
Looking this up.
Hospitals listed: Good Samaritan Hospital · Stanford Health Care · Stanford Health Care Tri-Valley. That is not proof they admit you there this week.
Plans that list them
1 plan · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Williams’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A140987 · Current
Licensed to practise in California · since 2016 · expires 2027-04-30 · Autonomous University of Guadalajara Faculty of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
3 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Good Samaritan HospitalSan Jose, CAAcute Care Hospital · Proprietary · Has an emergency department · Birthing-friendlyPart of HCA Healthcare, which runs 185 hospitals in 19 statesPatients rate it 2 of 5 · 67% would definitely recommend itOverall rating: 2 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.337, Oct 2024 – Sep 2025
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
- Stanford Health Care Tri-ValleyPleasanton, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Stanford Health Care, which runs 3 hospitalsPatients rate it 3 of 5 · 74% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.178, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.237, Oct 2024 – Sep 2025
See every measure and the patient survey for Good Samaritan Hospital
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 1 better, 6 the same, 1 worse of 8 measures. Readmissions: 0 better, 5 the same, 4 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.337 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.75 (0 to 1.67) · 1,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.84 (0.54 to 1.14) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 143.59 (98.7 to 188.49) · 98 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.7 · 45 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 100 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.7 · 270 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 11.3 · 573 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.6 · 820 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.5 · 482 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.3 · 3,711 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.12 (0 to 0.3) · 8,866 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.2 (0.01 to 0.38) · 9,051 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.65 (0.74 to 4.56) · 1,929 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.8 (0.21 to 3.39) · 670 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.33 (0.88 to 3.78) · 1,836 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 6.73 (0 to 13.46) · 669 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.58 (3.96 to 11.19) · 654 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.59 (0.13 to 3.04) · 496 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.27 (0 to 0.87) · 7,373 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.1 · 152 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 1.08 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.542 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.484 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.565 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.8 · 327 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 24.2 · 703 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 61.1 · 289 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 36.3 · 665 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 25.4 · 856 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 19 · 978 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.3 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 12.3 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 21.2 · 135 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.8 (10.1 to 18.6) · 129 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.2 (0.9 to 1.5) · 531 cases | No different | Jan 2024 – Dec 2024 |
What patients said (704 patients answered, 24% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 2 |
| Quietness | 1 |
| Recommend hospital | 3 |
| Room was "always" clean | 66% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 71% |
| Staff "always" explained | 54% |
| Yes, staff "did" give patients this information | 83% |
| Yes, staff "did" give patients information about help after discharge | 81% |
| Doctors "always" explained things so they could understand | 66% |
| Doctors "always" listened carefully | 69% |
| Doctors "always" treated them with courtesy and respect | 78% |
| Patients who gave a rating of "9" or "10" (high) | 63% |
| Staff "always" explained new medications | 68% |
| Nurses "always" explained things so they could understand | 69% |
| Nurses "always" listened carefully | 73% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 38% |
| "YES", patients would definitely recommend the hospital | 67% |
| Staff "always" explained possible side effects | 40% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
See every measure and the patient survey for Stanford Health Care Tri-Valley
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 7 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.178 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.237 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.79 (0 to 1.73) · 1,041 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.79 (0.5 to 1.08) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 145.81 (96.5 to 195.12) · 72 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.9 · 55 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.6 · 92 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.5 · 96 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.5 · 395 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 391 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 162 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 1,736 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.37) · 4,425 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.22 (0.02 to 0.41) · 4,771 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.45 (1.46 to 5.44) · 1,403 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.5 (0.05 to 2.94) · 645 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.81 (0.38 to 3.24) · 1,279 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.53 (3.2 to 13.85) · 639 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.15 (1.89 to 8.41) · 648 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.14 to 3.07) · 370 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.16 (0 to 0.83) · 4,160 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 74 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.369 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.112 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.1 · 110 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.1 · 437 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -5.8 · 94 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -19.3 · 456 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -0.3 · 402 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 15.8 · 358 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.8 (4.7 to 9.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.1 (7.5 to 13.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.9 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.3 · 92 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.4 (9.6 to 16.2) · 1,532 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.8 to 1.2) · 929 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,268 patients answered, 26% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 65% |
| Nurses "always" communicated well | 77% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 73% |
| Nurses "always" listened carefully | 74% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 42% |
| "YES", patients would definitely recommend the hospital | 74% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 89% |
Original Medicare doctor bills
$101,610
Medicare paid this office $101,610 for 486 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Critical care, first 30-74 minutes | 178 | $54,492 | $182 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 128 | $20,940 | $104 |
| Return visit (30+ min) | 62 | $7,211 | $81 |
| Return visit (30+ min) | 42 | $6,792 | $119 |
| New patient visit (60+ min) | 14 | $2,028 | $145 |
See all 11 services
| Critical care, first 30-74 minutes | 178 | $54,492 | $182 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 128 | $20,940 | $104 |
| Return visit (30+ min) | 62 | $7,211 | $81 |
| Return visit (30+ min) | 42 | $6,792 | $119 |
| New patient visit (60+ min) | 14 | $2,028 | $145 |
| Critical care, each additional 30 minutes | 16 | $1,482 | $93 |
| Long return visit (40+ min) | 12 | $1,479 | $123 |
| Test to examine how well the lungs exchange gases | 59 | $455 | $8 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 45 | $417 | $9 |
| Test to measure expiratory airflow and volume | 49 | $348 | $7 |
| Test to determine lung volumes using sensors | 24 | $254 | $11 |
Who their Medicare patients are
486 Original Medicare patients in 2024. Average age 76 · Under 65 10% · 85 and older 18% · Women 47% · Also on Medicaid 31% · Health risk score 2.42. Above the middle of the specialty; the typical pulmonary disease clinician is at 2.13.
Conditions among them: High blood pressure 75% · Coronary heart disease 50% · Chronic kidney disease 46% · COPD 45% · Diabetes 44% · Heart failure 44% · Atrial fibrillation 43% · Depression 28% · Dementia 25% · Cancer 22% · Stroke 21%.
The office billed $730,200, Medicare allowed $130,410 and paid $101,610; for 913 services of 23 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 486 | 913 | 76 | 2.42 | $730,200 | $101,610 |
| 2023 | 467 | 967 | 75 | 2.47 | $683,162 | $96,550 |
| 2022 | 457 | 1,013 | 74 | 2.34 | $698,254 | $100,956 |
| 2021 | 509 | 1,635 | 73 | 2.61 | $547,593 | $203,323 |
| 2020 | 580 | 2,099 | 72 | 2.96 | $611,882 | $264,338 |
| 2019 | 785 | 2,906 | 72 | 2.85 | $628,877 | $304,464 |
| 2018 | 357 | 1,177 | 72 | 2.79 | $232,194 | $129,085 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 11 services
| Critical care, first 30-74 minutes | 131 | $49,071 | $188 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 97 | $15,270 | $108 |
| Return visit (30+ min) | 99 | $13,294 | $89 |
| New patient visit (60+ min) | 37 | $5,908 | $160 |
| Long return visit (40+ min) | 26 | $3,923 | $135 |
| Critical care, each additional 30 minutes | 24 | $2,471 | $95 |
| Irrigation and suction of lung airways to obtain cells using an endoscope | 11 | $1,438 | $120 |
| Test to examine how well the lungs exchange gases | 97 | $784 | $8 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 71 | $665 | $9 |
| Test to determine lung volumes using sensors | 45 | $493 | $11 |
| Test to measure expiratory airflow and volume | 56 | $426 | $7 |
2022: 13 services
| Critical care, first 30-74 minutes | 107 | $40,029 | $191 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 123 | $22,857 | $93 |
| Return visit (30+ min) | 74 | $8,928 | $88 |
| New patient visit (60+ min) | 52 | $8,041 | $155 |
| Long return visit (40+ min) | 44 | $6,461 | $111 |
| Hospital discharge day management, 30 minutes or less | 23 | $1,600 | $67 |
| Critical care, each additional 30 minutes | 14 | $1,537 | $96 |
| Aspiration of fluid from chest cavity using imaging guidance | 11 | $1,146 | $95 |
| Short return visit (20+ min) | 11 | $757 | $58 |
| Test to examine how well the lungs exchange gases | 69 | $573 | $8 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 47 | $436 | $9 |
| Test to determine lung volumes using sensors | 32 | $355 | $11 |
| Test to measure expiratory airflow and volume | 44 | $341 | $7 |
2021: 12 services
| Critical care, first 30-74 minutes | 266 | $132,155 | $177 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 119 | $19,748 | $83 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 138 | $17,356 | $58 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 72 | $11,007 | $149 |
| Return visit (30+ min) | 54 | $6,352 | $84 |
| New patient visit (60+ min) | 16 | $2,807 | $175 |
| Critical care, each additional 30 minutes | 21 | $2,601 | $90 |
| Insertion of non-tunneled central venous tube for infusion (5 years or older) | 22 | $1,461 | $66 |
| Emergent insertion of breathing tube into windpipe using an endoscope | 13 | $1,411 | $101 |
| Test to examine how well the lungs exchange gases | 18 | $816 | $43 |
| Test to determine lung volumes using sensors | 18 | $752 | $40 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 17 | $571 | $32 |
2020: 14 services
| Critical care, first 30-74 minutes | 300 | $176,798 | $181 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 182 | $23,624 | $59 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 139 | $22,093 | $86 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 81 | $14,084 | $166 |
| Return visit (30+ min) | 74 | $9,447 | $84 |
| Critical care, each additional 30 minutes | 26 | $2,812 | $83 |
| Emergent insertion of breathing tube into windpipe using an endoscope | 19 | $2,234 | $118 |
| Insertion of non-tunneled central venous tube for infusion (5 years or older) | 22 | $1,675 | $70 |
| New patient visit (45+ min) | 16 | $1,647 | $103 |
| Short return visit (20+ min) | 44 | $1,420 | $31 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 11 | $1,231 | $112 |
| Test to examine how well the lungs exchange gases | 19 | $900 | $47 |
| Test to determine lung volumes using sensors | 19 | $868 | $46 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 18 | $829 | $46 |
2019: 18 services
| Critical care, first 30-74 minutes | 336 | $162,766 | $178 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 265 | $38,275 | $58 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 196 | $29,257 | $84 |
| Short return visit (20+ min) | 129 | $12,221 | $57 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 61 | $10,103 | $163 |
| Return visit (30+ min) | 76 | $9,582 | $83 |
| New patient visit (45+ min) | 65 | $7,204 | $111 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 64 | $6,937 | $108 |
| Critical care, each additional 30 minutes | 49 | $5,445 | $89 |
| Test to examine how well the lungs exchange gases | 80 | $3,343 | $42 |
| Test to determine lung volumes using sensors | 80 | $3,313 | $41 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 67 | $2,861 | $43 |
| Transitional care management services for problem of at least moderate complexity | 20 | $2,623 | $125 |
| Insertion of non-tunneled central venous tube for infusion (5 years or older) | 33 | $2,339 | $69 |
| Irrigation and suction of lung airways to obtain cells using an endoscope | 20 | $2,306 | $110 |
| Emergent insertion of breathing tube into windpipe using an endoscope | 11 | $1,251 | $114 |
| Test to measure expiratory airflow and volume | 17 | $507 | $30 |
| Evaluation of use of breathing device | 12 | $191 | $14 |
2018: 12 services
| Critical care, first 30-74 minutes | 135 | $68,274 | $178 |
| New patient visit (45+ min) | 105 | $13,824 | $132 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 111 | $13,298 | $59 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 61 | $9,013 | $84 |
| Short return visit (20+ min) | 63 | $5,516 | $60 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 35 | $3,860 | $110 |
| Return visit (30+ min) | 26 | $2,598 | $87 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 42 | $2,160 | $51 |
| Test to determine lung volumes using sensors | 44 | $2,050 | $47 |
| Test to examine how well the lungs exchange gases | 44 | $2,042 | $46 |
| Critical care, each additional 30 minutes | 17 | $1,610 | $89 |
| Insertion of non-tunneled central venous tube for infusion (5 years or older) | 17 | $1,355 | $80 |
Medicaid work
$316 in 2024
Medicaid paid $316 for 46 billed services this clinician did in 2024, up to 18 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Diffusing capacity | 30 | $160 |
| EVALUATION OF WHEEZING | 16 | $156 |
| 2024 | 46 | 2 | 18 | $316 |
| 2023 | 65 | 3 | 18 | $718 |
| 2022 | 191 | 3 | 17 | $8,188 |
| 2021 | 935 | 4 | 50 | $86,632 |
| 2020 | 999 | 3 | 46 | $89,081 |
| 2019 | 1,009 | 8 | 39 | $59,360 |
| 2018 | 360 | 4 | 30 | $26,324 |
See the largest Medicaid services in earlier years
2023
| Return visit (30+ min) | 15 | $381 |
| EVALUATION OF WHEEZING | 15 | $205 |
| Diffusing capacity | 35 | $131 |
2022
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 165 | $7,039 |
| Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes | 14 | $841 |
| Return visit (30+ min) | 12 | $308 |
2021
| Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes | 717 | $79,821 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 164 | $4,678 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 39 | $1,683 |
| Return visit (30+ min) | 15 | $450 |
2020
| Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes | 739 | $80,196 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 199 | $5,850 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 61 | $3,034 |
2019
| Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes | 404 | $38,346 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 389 | $12,172 |
| Short return visit (20+ min) | 112 | $3,039 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 41 | $1,842 |
| New patient visit (45+ min) | 23 | $1,783 |
| Diffusing capacity | 13 | $748 |
| Plethysmography for determination of lung volumes and, when performed, airway resistance | 13 | $746 |
| Critical care, evaluation and management of the critically ill or critically injured patient; each additional 30 minutes (List separately in addition to code for primary service) | 14 | $684 |
2018
| Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes | 140 | $12,760 |
| New patient visit (45+ min) | 87 | $8,813 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 114 | $4,089 |
| Short return visit (20+ min) | 19 | $663 |
Drugs they prescribed that Part D paid
$198,933
Pharmacies billed $198,933 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 659) in 2024. At or below the middle of the specialty; the typical pulmonary disease clinician is at 0%.
232 generic and 427 brand-name prescriptions · $198,933 in drug cost · 16 antibiotic prescriptions to 12 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Trelegy Ellipta | 93 | $67,646 | $727 |
| Spiriva Respimat | 49 | $27,868 | $569 |
| Breztri Aerosphere | 25 | $16,877 | $675 |
| Anoro Ellipta | 35 | $13,611 | $389 |
| Breo Ellipta | 23 | $10,589 | $460 |
See all 15 drugs
| Trelegy Ellipta | 93 | $67,646 | $727 |
| Spiriva Respimat | 49 | $27,868 | $569 |
| Breztri Aerosphere | 25 | $16,877 | $675 |
| Anoro Ellipta | 35 | $13,611 | $389 |
| Breo Ellipta | 23 | $10,589 | $460 |
| Symbicort | 28 | $9,762 | $349 |
| Incruse Ellipta | 25 | $8,662 | $346 |
| Budesonide-Formoterol | 26 | $5,717 | $220 |
| Breyna | 20 | $3,666 | $183 |
| Albuterol Sulfate Hfa | 102 | $2,790 | $27 |
| Ventolin Hfa | 13 | $718 | $55 |
| Fluticasone Propionate | 37 | $354 | $10 |
| Montelukast | 50 | $353 | $7 |
| Azithromycin | 11 | $288 | $26 |
| Prednisone | 39 | $166 | $4 |
Year by year
| 2024 | 659 | 94 | 0% (0) | 65% | $198,933 |
| 2023 | 517 | 99 | 0% (0) | 71% | $214,725 |
| 2022 | 453 | 111 | 0% (0) | 62% | $145,363 |
| 2021 | 635 | 91 | 0% (0) | 80% | $314,951 |
| 2020 | 680 | 96 | 0% (0) | 80% | $324,753 |
| 2019 | 757 | 117 | 0% (0) | 81% | $289,427 |
| 2018 | 203 | 54 | 0% (0) | 75% | $49,632 |
| 2016 | 13 | None | 0% (0) | None | $512 |
| 2015 | 145 | 16 | 0% (0) | None | $7,465 |
| 2014 | 64 | 16 | 0% (0) | None | $6,768 |
| 2013 | 53 | None | 0% (0) | 32% | $2,372 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 13 drugs
| Trelegy Ellipta | 68 | $47,265 | $695 |
| Symbicort | 60 | $26,719 | $445 |
| Spiriva Respimat | 41 | $22,531 | $550 |
| Breztri Aerosphere | 29 | $19,674 | $678 |
| Breo Ellipta | 29 | $11,952 | $412 |
| Incruse Ellipta | 15 | $8,313 | $554 |
| Advair Diskus | 17 | $7,789 | $458 |
| Anoro Ellipta | 11 | $5,472 | $497 |
| Albuterol Sulfate Hfa | 62 | $2,246 | $36 |
| Ventolin Hfa | 24 | $1,504 | $63 |
| Montelukast | 48 | $629 | $13 |
| Fluticasone Propionate | 19 | $446 | $23 |
| Prednisone | 22 | $90 | $4 |
2022: 12 drugs
| Trelegy Ellipta | 53 | $36,419 | $687 |
| Symbicort | 30 | $17,755 | $592 |
| Breo Ellipta | 38 | $17,603 | $463 |
| Spiriva Respimat | 32 | $17,338 | $542 |
| Daliresp | 16 | $10,584 | $662 |
| Stiolto Respimat | 14 | $8,828 | $631 |
| Breztri Aerosphere | 13 | $8,172 | $629 |
| Incruse Ellipta | 12 | $7,370 | $614 |
| Albuterol Sulfate Hfa | 70 | $2,898 | $41 |
| Ventolin Hfa | 18 | $964 | $54 |
| Montelukast | 50 | $843 | $17 |
| Prednisone | 15 | $81 | $5 |
2021: 17 drugs
| Xolair | 20 | $55,953 | $2,798 |
| Trelegy Ellipta | 54 | $52,453 | $971 |
| Spiriva Respimat | 65 | $36,186 | $557 |
| Breo Ellipta | 47 | $29,840 | $635 |
| Symbicort | 49 | $26,131 | $533 |
| Daliresp | 14 | $9,744 | $696 |
| Incruse Ellipta | 19 | $9,285 | $489 |
| Breztri Aerosphere | 13 | $9,195 | $707 |
| Stiolto Respimat | 14 | $7,443 | $532 |
| Anoro Ellipta | 15 | $6,885 | $459 |
| Budesonide-Formoterol | 22 | $6,593 | $300 |
| Albuterol Sulfate Hfa | 124 | $6,208 | $50 |
| Arnuity Ellipta | 19 | $5,131 | $270 |
| Ventolin Hfa | 44 | $2,807 | $64 |
| Montelukast | 45 | $665 | $15 |
| Fluticasone Propionate | 17 | $235 | $14 |
| Prednisone | 15 | $45 | $3 |
2020: 15 drugs
| Xolair | 31 | $89,525 | $2,888 |
| Spiriva Respimat | 76 | $41,548 | $547 |
| Breo Ellipta | 79 | $40,250 | $509 |
| Trelegy Ellipta | 42 | $34,035 | $810 |
| Symbicort | 48 | $25,151 | $524 |
| Daliresp | 23 | $12,659 | $550 |
| Incruse Ellipta | 28 | $11,572 | $413 |
| Advair Diskus | 12 | $6,029 | $502 |
| Arnuity Ellipta | 22 | $5,961 | $271 |
| Ventolin Hfa | 77 | $5,653 | $73 |
| Stiolto Respimat | 12 | $5,424 | $452 |
| Albuterol Sulfate Hfa | 56 | $2,893 | $52 |
| Montelukast | 65 | $913 | $14 |
| Fluticasone Propionate | 13 | $366 | $28 |
| Prednisone | 21 | $88 | $4 |
2019: 16 drugs
| Xolair | 18 | $81,237 | $4,513 |
| Trelegy Ellipta | 55 | $39,983 | $727 |
| Breo Ellipta | 84 | $38,755 | $461 |
| Spiriva Respimat | 74 | $36,545 | $494 |
| Symbicort | 67 | $26,082 | $389 |
| Daliresp | 27 | $10,715 | $397 |
| Ventolin Hfa | 134 | $9,547 | $71 |
| Stiolto Respimat | 17 | $8,718 | $513 |
| Incruse Ellipta | 20 | $6,766 | $338 |
| Arnuity Ellipta | 23 | $5,112 | $222 |
| Proair Hfa | 26 | $2,429 | $93 |
| Albuterol Sulfate Hfa | 24 | $1,328 | $55 |
| Montelukast | 57 | $712 | $12 |
| Fluticasone Propionate | 21 | $440 | $21 |
| Prednisone | 34 | $164 | $5 |
| Azithromycin | 16 | $136 | $8 |
2018: 5 drugs
| Spiriva Respimat | 23 | $10,220 | $444 |
| Breo Ellipta | 22 | $9,095 | $413 |
| Trelegy Ellipta | 15 | $8,986 | $599 |
| Ventolin Hfa | 56 | $3,503 | $63 |
| Prednisone | 19 | $63 | $3 |
2015: 2 drugs
| Proair Hfa | 13 | $663 | $51 |
| Metformin | 14 | $45 | $3 |
Money from drug and device companies
$237 in 2021
| 2021 | 6 | 12 | None | $237 |
| 2020 | 5 | 8 | None | $170 |
| 2019 | 12 | 59 | None | $799 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Boehringer Ingelheim Pharmaceuticals | Ofev | $60 | 2 payments
|
| AbbVie | Dalvance | $57 | 3 payments
|
| United Therapeutics | Orenitram | $47 | 3 payments
|
| Janssen Pharmaceuticals | Xarelto | $29 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Fasenra | $27 | 2 payments
|
| Insmed | Arikayce | $16 | 1 payment
|
See all 12 published payments
| Insmed | Education · 2021-08-24 | Arikayce | $16 |
| AbbVie | Meals · 2021-05-27 | Dalvance | $23 |
| AstraZeneca Pharmaceuticals LP | Meals · 2021-05-26 | Farxiga | $12 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2021-05-25 | Ofev | $13 |
| United Therapeutics | Meals · 2021-05-25 | Orenitram | $18 |
| AbbVie | Meals · 2021-05-11 | Avycaz | $14 |
| United Therapeutics | Meals · 2021-04-28 | Orenitram | $8 |
| Boehringer Ingelheim Pharmaceuticals | Education · 2021-04-22 | Ofev | $47 |
| United Therapeutics | Meals · 2021-03-11 | Orenitram | $21 |
| Janssen Pharmaceuticals | Meals · 2021-03-10 | Xarelto | $29 |
| AstraZeneca Pharmaceuticals LP | Meals · 2021-03-09 | Fasenra | $15 |
| AbbVie | Meals · 2021-03-03 | Dalvance | $20 |
See earlier years (2020, 2019)
2020: $170
| Actelion Pharmaceuticals US | Opsumit | $50 | 2 payments
|
| Boehringer Ingelheim Pharmaceuticals | Ofev | $43 | 2 payments
|
| AstraZeneca Pharmaceuticals LP | Breztri Aerosphere | $38 | 2 payments
|
| Takeda Pharmaceuticals U.S.A. | Glassia | $23 | 1 payment
|
| United Therapeutics | Orenitram | $15 | 1 payment
|
2019: $799
| Boehringer Ingelheim Pharmaceuticals | Stiolto Respimat | $239 | 22 payments
|
| AstraZeneca Pharmaceuticals LP | Symbicort | $114 | 4 payments
|
| GlaxoSmithKline | Trelegy Ellipta | $110 | 7 payments
|
| Philips Electronics North America | Incourage | $82 | 4 payments
|
| Actelion Pharmaceuticals US | Uptravi | $79 | 4 payments
|
| Novartis Pharmaceuticals | Xolair | $51 | 3 payments
|
| Shire North American Group | Glassia | $39 | 2 payments
|
| Sunovion Pharmaceuticals | Lonhala Magnair | $21 | 1 payment
|
| Merck Sharp & Dohme | Zerbaxa | $19 | 1 payment
|
| Insmed | Arikayce | $17 | 1 payment
|
| Mylan Specialty L.P. | Yupelri | $16 | 1 payment
|
| Gilead Sciences | None | $13 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 94.9 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1396007100
- Licence
- CA A140987California A140987: Current · expires 2027-04-30
- Group
- Stanford Health Care · University Healthcare Alliance
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RC0200X (207RC0200X); Internal medicine (207R00000X); Federal specialty code 207RP1001X (207RP1001X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2012-06-08
- NPI last updated
- 2024-04-12
- NPI record certified
- 2024-04-12
This is when the NPI record was last certified, not a medical board exam.